NattoPharma and KD Nutra have entered into a partnership agreement to promote KD-PüR high concentrate omega-3s and MenaQ7 PharmaPure MK-7 combination
NattoPharma has entered into a partnership agreement with KD Nutra – a KD Pharma Group company – to create an innovative cardiovascular-support ingredient that combines KD Nutra’s KD-PüR high concentrate omega-3s with NattoPharma’s category leading nature-identical Vitamin K2, MenaQ7 PharmaPure MK-7.
The exclusive partnership for KD-Pür EPA and DHA ≥70% concentrates and MenaQ7 K2 is available as part of the K2ardio3 Platform, and offers a variety of custom formulations including complementary CV ingredients such as plant sterols.
KD’s formulation expertise allows for proprietary blends and delivery options.
Omega-3s are widely known and accepted for their cardiovascular benefits, and KD Pharma’s high concentrate ingredients speak directly to this advantage.
KD-Pür technology gently extracts and purifies omega-3s in a pharmaceutical GMP certified facility. This advanced technology is capable of purifying highly sensitive omega-3s without the use of excessive heat, chemical solvents (green technology) or oxygen.
NattoPharma will provide the missing piece of the cardiovascular puzzle with MenaQ7 PharmaPure MK-7: MenaQ7 is the only vitamin K2 as MK-7 clinically proven to provide benefits for heart health, including maintaining and promoting arterial flexibility.
MenaQ7 PharmaPure K2 was developed for its Rx division Kaydence Pharma and is part of several ongoing patient studies.
Further, in addition to having two US patents for cardiovascular benefits, NattoPharma’s MenaQ7 is patent pending for the combination of omega-3s and vitamin K2.
“NattoPharma has been incubating a number of new concepts based on our high standard of clinical validation confirming true health benefits,” says NattoPharma CEO Kjetil Ramsøy.
“KD Nutra’s rich history of innovation and stringent quality standards fits perfectly with NattoPharma’s principles, and the time is right to deliver an unsurpassed cardiovascular combination ingredient to the market.”
“With this exclusive partnership, KD Nutra’s K2ardio3 platform can provide unique and comprehensive lipid and blood vessel management products for an increasing health ageing demand,” says Scott Woodruff, CEO of KD Nutra.